Sanofi stock: Seawolf deal worth up to EUR 1.2 billion; down 0.37% premarket at EUR 85.90
Published on 11/19/2026 at 08:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for Sanofi investors
- Sanofi and Seawolf Therapeutics agreed a multi-target research collaboration and exclusive license deal.
- The partnership covers bleeding disorders and other undisclosed indications.
- Seawolf may receive up to EUR 1.2 billion in research, development and commercial milestones, plus tiered royalties.
Sanofi stock traded at 85.90 euros on Lang & Schwarz at 08:45 CET on Thursday, November 19, 2026, 0.37 percent below the Xetra close of Wednesday, November 18.
Sanofi develops and sells medicines and vaccines across areas including immunology, rare diseases, neurology and consumer healthcare. The company is adding a new early-stage DNA medicines partnership to that portfolio.
Seawolf partnership expands pipeline options
On November 16, Seawolf Therapeutics announced a multi-target research collaboration and exclusive license agreement with Sanofi. The partnership covers undisclosed therapies for bleeding disorders and additional unnamed indications. Seawolf said the agreement could generate up to EUR 1.2 billion in research, development and commercial milestones, as well as tiered royalties on potential product sales. The company also announced EUR 100 million in financing to advance its TRIDENT lipid nanoparticle-based DNA delivery platform.
BusinessWire reported that Seawolf's platform is designed to deliver DNA payloads into cell nuclei and support longer-term protein expression. The company said its lead proprietary program targets metabolic diseases, while the Sanofi collaboration adds external programs to its development portfolio. The agreement remains tied to research, development and commercial milestones rather than an approved product.
European investors will also track the CAC 40 for broader direction.
BusinessWire reported the financing and partnership terms. More news and analyses on Sanofi stock.
